No quarterly revenue total was found in SpyGlass Pharma, Inc.'s SEC filings.
SpyGlass Pharma, Inc. (SGP) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. Free cash flow was -$16.8 million. As of Jun 30, 2026 it held $223.1 million in cash and investments and $1.6 million in total debt.
Revenue
—
Net income
$-19.86M
-43.8% vs prior quarter
Operating cash flow
$-14.84M
-9.6% vs prior quarter
Free cash flow
$-16.77M
-17.9% vs prior quarter
EPS
$-0.59
+14.5% vs prior quarter
Dividend per share
None
Shares outstanding
33.45M
+0.0% vs prior quarter
Net cash
$221.51M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- SGP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1778922
- Former names
- SpyGlassPharma, Inc. (until Jun 5, 2025); SpyGlass Ophthalmics, Inc. (until Jan 5, 2021)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
|---|---|---|
| Operating income | -$22.0M | -$15.4M |
| Net income | -$19.9M | -$13.8M |
| Diluted EPS | -$0.59 | -$0.69 |
| Operating cash flow | -$14.8M | -$13.5M |
| Free cash flow | -$16.8M | -$14.2M |
| Total assets | $243.4M | $258.4M |
| Total liabilities | $11.1M | $8.3M |
| Stockholders' equity | $232.4M | $250.1M |
| Cash and investments | $223.1M | $238.9M |
| Total debt | $1.6M | $1.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 19, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 1, 2026 | Oct 1, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 14, 2026 | May 14, 2026 |
All 92 SpyGlass Pharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.